A randomized simultaneous comparison of acceleromyography with a peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular blockade with sugammadex

2010 ◽  
Vol 27 (10) ◽  
pp. 866-873 ◽  
Author(s):  
Leon Drobnik ◽  
Harald J Sparr ◽  
Sven-Egron Thörn ◽  
Karin S Khuenl-Brady ◽  
Henk Rietbergen ◽  
...  
Keyword(s):  
Peripheral Nerve ◽  
Neuromuscular Blockade ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator ◽  
Simultaneous Comparison

Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU

1996 ◽  
Vol 5 (6) ◽  
pp. 449-454 ◽  
Author(s):  
R Kleinpell ◽  
C Bedrosian ◽  
L McCormick ◽  
M Kremer ◽  
L Bujalski ◽  
...  
Keyword(s):  
Peripheral Nerve ◽  
Neuromuscular Blockade ◽  
National Sample ◽  
Neuromuscular Blocking ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator ◽  
Number Of Patients ◽  
Train Of Four ◽  
Current Monitoring ◽  
Prolonged Neuromuscular Blockade

BACKGROUND: Neuromuscular blockade is a frequently used therapy in the ICU. However, recent reports of prolonged paralysis and general muscular weakness in patients treated with this procedure have raised concerns about its use in intensive care. OBJECTIVE: The purpose of this study was to assess current monitoring practices of nurses who care for patients treated with neuromuscular blockade. METHODS: In January 1995, questionnaires were mailed to a random national sample of 2000 critical care nurses. Of the 2000 questionnaires mailed, 744 were returned. RESULTS: The number of patients per month who were treated with neuromuscular blockade in ICU settings ranged from 0 to 75 (mean = 6.82, SD = 9.15). For each patient, the average number of days of blockade ranged from less than 1 to 63 (mean = 4.12, SD = 3.36). The most common indications for neuromuscular blockade were to assist in mechanical ventilation, reduce oxygen consumption, and treat agitation. Only 41% of respondents (n = 306) reported using train-of-four stimuli and a peripheral nerve stimulator to monitor patients. Depth of neuromuscular blockade was routinely monitored by using clinical assessment (31%), a peripheral nerve stimulator (16%), or both (52%). CONCLUSIONS: Among the respondents, variations existed in monitoring practices and in the use of peripheral nerve stimulators, including the frequency of monitoring and use of the baseline milliamperage. Appropriate monitoring and titration of neuromuscular blocking agents by ICU nurses may aid in preventing adverse effects, including the potential for prolonged neuromuscular blockade. The existing variations in practice may affect patients' outcomes.

Neuromuscular Blockade in the Pediatric Intensive Care Unit: Pancuronium, Vecuronium, Rocuronium, or Atracurium

1997 ◽  
Vol 12 (4) ◽  
pp. 213-217 ◽  
Author(s):  
Joseph D. Tobias
Keyword(s):  
Intensive Care Unit ◽  
Renal Function ◽  
Intensive Care ◽  
Peripheral Nerve ◽  
Continuous Infusion ◽  
Neuromuscular Blockade ◽  
Pediatric Intensive Care Unit ◽  
Pediatric Intensive Care ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator

Certain conditions may necessitate use of neuromuscular blocking agents (NMBAs) in children in the pediatric intensive care unit (PICU). Despite information concerning individual agents, there are limited studies comparing agents. I compare 4 of the more commonly used NMBAs: pancuronium, vecuronium, rocuronium, and atracurium. All agents were administered by bolus followed by a continuous infusion with the rate adjusted by use of a peripheral nerve stimulator to maintain one twitch of the train-of-four. Ten patients with normal hepatic and renal function were included in each group. The study period included the first 72 hours of neuromuscular blockade. All 4 agents were easily titrated by continuous infusion to maintain the desired level of blockade. Pancuronium infusion requirements varied from 0.03 to 0.12 mg/kg/hr, vecuronium requirements from 0.05 to 0.2 mg/kg/hr, rocuronium requirements from 0.5 to 1.9 mg/kg/hr, and atracurium requirements from 0.8 to 2.2 mg/kg/hr. No significant advantage of one agent over another was noted. The wide range of infusion requirements further stresses the need for close monitoring of the degree of neuromuscular blockade with a peripheral nerve stimulator. An additional 10 patients with abnormal hepatic/renal function received atracurium. The dose requirements were the same as in patients with normal end-organ function, ranging from 0.6 to 2.0 mg/kg/hr. In patients with abnormal hepatic or renal function, atracurium may be used without the need to alter the dose.

Failure to Reverse Prolonged Vecuronium-Induced Neuromuscular Blockade with Edrophonium in an Anesthetized Dog

2011 ◽  
Vol 47 (4) ◽  
pp. 294-298 ◽  
Author(s):  
Manuel Martin-Flores ◽  
Jordyn Boesch ◽  
Luis Campoy ◽  
Robin D. Gleed
Keyword(s):  
Peripheral Nerve ◽  
Neuromuscular Blockade ◽  
Neuromuscular Transmission ◽  
Muscle Relaxation ◽  
Complete Recovery ◽  
Neuromuscular Function ◽  
Partial Recovery ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator ◽  
Factors Affecting

A case of prolonged muscle relaxation after vecuronium in an anesthetized dog is presented. After using peripheral nerve stimulation to confirm partial recovery of neuromuscular transmission, administration of 0.5 mg/kg IV of intravenous edrophonium failed to complete the reversal process. Subsequent administration of neostigmine resulted in complete recovery from blockade. Without monitoring neuromuscular function with a peripheral nerve stimulator until reversal was complete, it was very likely this patient would have been extubated with incomplete neuromuscular transmission. Several factors affecting the duration of neuromuscular blockade and its reversal are addressed.

Monitoring neuromuscular blockade in the adult ICU

1995 ◽  
Vol 4 (2) ◽  
pp. 122-130 ◽  
Author(s):  
EV Ford
Keyword(s):  
Side Effects ◽  
Peripheral Nerve ◽  
Neuromuscular Blockade ◽  
Clinical Signs ◽  
Neuromuscular Blocking ◽  
Neuromuscular Blocking Agents ◽  
Individual Response ◽  
Nerve Stimulator ◽  
Peripheral Nerve Stimulator ◽  
Proper Operation

Although neuromuscular blocking agents are now administered in intensive care units for extended periods, no standard has been established for their use in critically ill patients. Also, despite wide variations in individual response to neuromuscular blockade, the level of paralysis is not monitored consistently. Paralytic agents are associated with numerous side effects such as prolonged weakness, which is gaining widespread attention. Side effects may be minimized or prevented by consistent and precise monitoring of the degree of blockade. Monitoring is best accomplished by the expert use of the peripheral nerve stimulator. The evoked responses must be correlated with clinical signs of muscle movement. Furthermore, staff education regarding the pharmacology of these agents and the proper operation of the peripheral nerve stimulator must be ongoing.

Prospective case series on the use of peripheral nerve stimulation for focal mononeuropathy treatment

2019 ◽  
Vol 9 (6) ◽  
pp. 551-558 ◽  
Author(s):  
Jessica Oswald ◽  
Varun Shahi ◽  
Krishnan V Chakravarthy
Keyword(s):  
Peripheral Nerve ◽  
Case Series ◽  
Suprascapular Nerve ◽  
Intercostal Nerve ◽  
Nerve Stimulator ◽  
Patient Case ◽  
Peripheral Nerve Stimulator ◽  
Pain Scores ◽  
Early Results ◽  
Prospective Case Series

Aim: This case series looks at outcomes in 39 patients implanted using the Bioness Stimrouter system on various isolated mononeuropathies. Patients & methods: A case series of 39 patients with a total of 42 implants were enrolled starting August 2017 at various pain management centers. Results: Of 39 patients studied, 78% of the participants noticed an improvement in their pain. There was a 71% reduction in pain scores with the average preprocedure score of 8 improving to 2 post-implant. Participants noted on average a 72% improvement in activity with the greatest observed in the brachial plexus (80%) and suprascapular nerve (80%) and smallest in the intercostal nerve (40%). Approximately 89% of those implanted with a peripheral nerve stimulator experienced a greater than 50% reduction in opioid consumption. Conclusion: Peripheral nerve stimulators are a new, minimally invasive neuromodulation modality that shows promising early results in our 39-patient case series.

Sign in / Sign up

Export Citation Format

Share Document